Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy

Summary

This study evaluates changes in skin quality and self-esteem among breast cancer patients who are initiating aromatase inhibitor therapy.

Eligibility

Inclusion Criteria:

* \* Female ≥ 18 years

  * Postmenopausal women suitable to receive aromatase inhibitor as per physician's discretion
  * Histologically confirmed adenocarcinoma of the breast stage 0-III with estrogen receptor (ER) and/or progesterone receptor (PR) positive per American Society of Clinical Oncology (ASCO)/ College of American Pathologists (CAP) guideline and any human epidermal growth factor receptor 2 (HER2)
  * Patients must not have received any prior chemotherapy or endocrine therapy for their current breast cancer. Patients who received tamoxifen or raloxifene or another agent for prevention of breast cancer may be included
  * Patients willing to avoid any facial procedures including facials, neurotoxin injections, fillers, or lasers during study period
  * Willing and able to provide consent

Exclusion Criteria:

* \* Patients who have previously taken AIs

  * Patients using prescription tretinoin, neurotoxin injections, fillers, facial lasers, microneedling, or facials within 6 months of study consent

Conditions9

Locations1 site

Browse More Trials